Myelosuppressive antineoplastic agents Drugs which potentiate the release of neutrophils eg lithium

Musculoskeletal pain Bone pain Splenic enlargement Hepatomegaly Thrombocytopenia Anaemia Epistaxis Headache, Vomiting Diarrhea Urinary abnormalites Osteoporosis Exacerbation of rheumatoid arthiritis Transcient decrease in blood glucose Raised uric acid levels

Myeloid malignancies not to be used within 24 hrs of cytotoxic chemotherapy due to sensitivity of rapidly dividing myeloid cells Severe congenital neutropenia Special precautions Premalignant or malignant myeloid conditions Sickle cell disease Osteoporic bone marrow disease Withdraw treatment if there are signs of pulmonary infiltrates Fluid retention or heart failure Monitor CBC and platelet count during therapy Monior bone density in patients with osteoporosis( long term treatment)

Dosage-

Starting dose is 5mmcg/kg/day given as single daily injection by SC bolus inj , by short IV infusion ( 5 to 30 minutes ) or by as continous iv or sc infusion

Obtain CBC and platelet count before intituting therapy, monitor twice weekly during therapy